Case report: Glycemic instability despite fasting C-peptide recovery during sequential somatostatin receptor ligand therapy in acromegaly with diabetes
- 1Department of Endocrinology, The Second Affiliated Hospital of Soochow University
- 2Department of Clinical Nutrition, The Second Affiliated Hospital of Soochow University
Abstract
Background: Somatostatin receptor ligands (SRLs) may improve glucose metabolism by reducing growth hormone excess, but they can also suppress insulin secretion. Severe hyperglycemia is well recognized with pasireotide. Less is known about glycemic stability after recovery from severe decompensation and during later changes in SRL therapy.
Case presentation: A 32-year-old woman with diabetes had persistent acromegaly despite transsphenoidal surgery, Gamma Knife radiosurgery, cabergoline, octreotide, and lanreotide. Pasireotide long-acting release 40 mg lowered growth hormone and insulin-like growth factor 1, but approximately 1 month later was followed by diabetic ketoacidosis and a fasting C-peptide of 0.38 ng/mL. Pasireotide was stopped, insulin-based treatment was given, and octreotide was resumed. Fasting C-peptide increased to 3.09 ng/mL within 2 months. During lanreotide re-exposure in 2025, HbA1c was 9.3% despite fasting C-peptide within the reference interval and no parallel deterioration in biochemical disease control. After lanreotide withdrawal and adjustment of diabetes therapy, intermittent hyperglycemia continued, although HbA1c decreased to 6.3% by July 2026.
Conclusions: Return of fasting C-peptide into the reference interval after pasireotide-associated diabetic ketoacidosis did not predict sustained glycemic stability in this patient. The later deterioration during lanreotide therapy was temporally associated with treatment but does not establish causality. The overall course is more consistent with persistent metabolic vulnerability despite normalization of fasting C-peptide than with confirmed recurrent SRL-induced dysglycemia. Glucose monitoring should be intensified when an SRL is started or changed in patients with diabetes or previous ketosis.
Related
- Preoperative HbA1c and postoperative day 1 fasting plasma glucose are associated with early glycemic improvement after transsphenoidal surgery in patients with acromegaly and preoperative dysglycemia: a retrospective cohort study.
- Editorial: Cancer risk in patients with acromegaly – is extensive screening needed?, volume II
- Evaluation of Diastolic Dysfunction in Pituitary Adenomas: A Comparative Single-Center Study Among Acromegaly, Prolactinoma, and Nonfunctioning Pituitary Adenomas
- Handgrip Strength Relative to Estimated Skeletal Muscle Mass and Threshold-Defined Physical Performance in Biochemically Controlled Acromegaly: A Cross-Sectional Study
- Development of Marine-Lenhart Syndrome during the Course of Acromegaly
BibTeX
@article{zhu2026case,
title = {{Case report: Glycemic instability despite fasting C-peptide recovery during sequential somatostatin receptor ligand therapy in acromegaly with diabetes}},
author = {Yewen Zhu and Yunwen Tao and Qimin Ding and Sicheng Li and Heming Guo and Wei Zhang and Yun Huang and Chen Fang},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.1954768},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1954768/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case report: Glycemic instability despite fasting C-peptide recovery during sequential somatostatin receptor ligand therapy in acromegaly with diabetes
AU - Yewen Zhu
AU - Yunwen Tao
AU - Qimin Ding
AU - Sicheng Li
AU - Heming Guo
AU - Wei Zhang
AU - Yun Huang
AU - Chen Fang
PY - 2026
DA - 2026/11/04
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1954768
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1954768/full
AB - Background: Somatostatin receptor ligands (SRLs) may improve glucose metabolism by reducing growth hormone excess, but they can also suppress insulin secretion. Severe hyperglycemia is well recognized with pasireotide. Less is known about glycemic stability after recovery from severe decompensation and during later changes in SRL therapy. Case presentation: A 32-year-old woman with diabetes had persistent acromegaly despite transsphenoidal surgery, Gamma Knife radiosurgery, cabergoline, octreotide, and lanreotide. Pasireotide long-acting release 40 mg lowered growth hormone and insulin-like growth factor 1, but approximately 1 month later was followed by diabetic ketoacidosis and a fasting C-peptide of 0.38 ng/mL. Pasireotide was stopped, insulin-based treatment was given, and octreotide was resumed. Fasting C-peptide increased to 3.09 ng/mL within 2 months. During lanreotide re-exposure in 2025, HbA1c was 9.3% despite fasting C-peptide within the reference interval and no parallel deterioration in biochemical disease control. After lanreotide withdrawal and adjustment of diabetes therapy, intermittent hyperglycemia continued, although HbA1c decreased to 6.3% by July 2026. Conclusions: Return of fasting C-peptide into the reference interval after pasireotide-associated diabetic ketoacidosis did not predict sustained glycemic stability in this patient. The later deterioration during lanreotide therapy was temporally associated with treatment but does not establish causality. The overall course is more consistent with persistent metabolic vulnerability despite normalization of fasting C-peptide than with confirmed recurrent SRL-induced dysglycemia. Glucose monitoring should be intensified when an SRL is started or changed in patients with diabetes or previous ketosis.
SN - 1664-2392
ER -